Drug Profile


Alternative Names: G-146034; GLPG-0634; GS-6034

Latest Information Update: 23 Jul 2017

Price : $50

At a glance

  • Originator Galapagos NV
  • Developer Galapagos NV; Gilead Sciences
  • Class 2 ring heterocyclic compounds; Amides; Anti-inflammatories; Antirheumatics; Cyclopropanes; Pyridines; Small molecules; Thiamorpholines; Triazoles
  • Mechanism of Action Janus kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Crohn's disease; Rheumatoid arthritis; Ulcerative colitis
  • Phase II Ankylosing spondylitis; Cutaneous lupus erythematosus; Psoriatic arthritis; Sjogren's syndrome

Most Recent Events

  • 05 Jul 2017 Gilead Sciences plans a phase II trial for Uveitis (Non-infectious, Treatment-experienced) in August 2017 (PO) (NCT03207815)
  • 21 Jun 2017 Galapagos initiates enrolment in the phase II trial for Psoriatic arthritis in Spain (PO) (EudraCT2017-000545-52)
  • 20 Jun 2017 Interim efficacy and adverse events data from the phase II DARWIN 3 trial in Rheumatoid arthritis released by Galapagos
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top